Logo

Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Share this

Allergan and Editas Report First Patient Dosing in P-I/II BRILLIANCE Study with AGN-151587 (EDIT-101) to Treat LCA10

Shots:

  • The P-I/II study will assess the safety & efficacy of AGN-151587 (subretinal injection) in ~18 patients with Leber congenital amaurosis 10. The patients enrolled are both adult & pediatric patients (aged 3-17yrs.)
  • The first patients dosing in BRILLIANCE study marks a significant milestone toward delivering the CRISPR medicines- treating the devastating LCA10
  • AGN-151587 (EDIT-101) is a CRISPR-based investigational therapy- intended to treat LCA10 and is administered via a subretinal injection to deliver the gene-editing machinery directly to photoreceptor cells

Click here ­to­ read full press release/ article | Ref: Editas | Image: Pharma Advancement


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions